Skip to content
Book Now

Educational only — not medical advice. This page explains the published mechanism of a prescription treatment for general education. Botox (onabotulinumtoxinA) is a prescription medicine, FDA-approved for the prevention of headaches in adults with chronic migraine. This is not a diagnosis, not a treatment plan, and not a substitute for evaluation by a qualified clinician.

Botox for Chronic Migraine: Not the Muscles, the Nerve Endings

A 72-second narrated mechanism animation on how onabotulinumtoxinA prevents chronic migraine, with the full transcript and the peer-reviewed references behind every claim — so you can check what the science actually says.

Mechanism animation · about 72 seconds · narrated · 9:16 vertical. Educational only — not medical advice.

Transcript

What the video says, beat by beat

  1. Shot 1 · Hook · ~10s

    It doesn't relax muscles

    “Everyone assumes Botox for migraine relaxes muscles. It doesn't. Chronic migraine, headache more days than not, is a nerve disease.”[1,2]

  2. Shot 2 · Anatomy · ~8s

    The alarm wires

    “A web of sensory nerves wraps your scalp and the lining around your brain. Their tiny endings are the alarm wires.”[1,3]

  3. Shot 3 · Attack · ~11s

    The attack is chemistry

    “In an attack those endings release signaling chemicals, CGRP among them, inflaming the lining, sensitizing the system. That pain is real.”[1,4]

  4. Shot 4 · The drug · ~10s

    It locks the release

    “Botox slips into those endings and cuts the docking protein, SNAP-25, so the packets can't release. Fewer alarms reach the brain.”[1,5,6,7]

  5. Shot 5 · The map · ~10s

    A map, not random

    “So it's a map of small injections across the forehead, the temples, the back of the head and the neck, following the nerves, plus a few where it hurts.”[8,9]

  6. Shot 6 · What to expect · ~11s

    Usual versus rare

    “Usually, it's a sore neck or a heavy eyelid for a few weeks. Rarely, trouble swallowing, breathing, or weakness that spreads. If that happens, call your doctor.”[10,15]

  7. Shot 7 · Close · ~10s

    Prevention, not rescue

    “This is prevention, not rescue. It's approved for chronic migraine, the goal is fewer headache days, and it builds over repeated cycles. Educational only. See a specialist.”[11,12,13,14,15]

“Headache more days than not” is the plain-language version of the formal definition: chronic migraine means headache on 15 or more days a month for more than three months, with migraine features on at least eight of those days[2] — a condition affecting roughly one to two in a hundred adults.[16]

What the science says

References

According to PubMed: every journal reference below was re-verified against its live PubMed record on September 3, 2026; the prescribing-information reference is the current DailyMed label (updated November 18, 2023). Numeric findings from individual studies are attributed to those studies and are not promises of results. No clinic-specific dosing appears on this page.

  1. Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache. 2020;60(7):1259-1272.

    Covers: the traditional “reducing muscle contractions” mechanism is insufficient to explain efficacy in migraine, which is primarily a sensory neurological disease; the toxin cleaves SNAP-25 in sensory as well as motor nerves, reducing release of CGRP, substance P and glutamate from the afferents that drive peripheral and central sensitization, so fewer pain signals reach the brain — the “it doesn't relax muscles” and “fewer alarms reach the brain” beats. Two authors were employees of the manufacturer; the mechanism is corroborated by the independent laboratory work in references 4, 6 and 7.

    PubMed · PMID 32602955 · DOI · 10.1111/head.13849

  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (ICHD-3), section 1.3: Chronic migraine. Cephalalgia. 2018;38(1):1-211.

    Covers: the formal definition — headache on 15 or more days a month for more than three months, with migraine features on at least eight days a month — behind “headache more days than not”

    PubMed · PMID 29368949 · DOI · 10.1177/0333102417738202 · ICHD-3 online · §1.3

  3. Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol. 2014;171(18):4177-4192.

    Covers: migraine pain arises from trigeminal afferents that innervate the meningeal vasculature (the “lining around your brain”); toxin delivered under the scalp is taken up by local afferent terminals and cleaves the SNARE proteins that release is built on — the “alarm wires” beat

    PubMed · PMID 24819339 · DOI · 10.1111/bph.12763

  4. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35-42.

    Covers: in cultured trigeminal nerve cells, stimulated release of CGRP was greatly repressed by therapeutic concentrations of botulinum toxin A while baseline release was unaffected — the “CGRP among them” beat, and why the drug blocks the attack signal rather than normal function

    PubMed · PMID 14979881 · DOI · 10.1111/j.1526-4610.2004.04007.x

  5. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-549.

    Covers: how the toxin binds the nerve ending, crosses into it, and, as a metalloprotease, cuts the proteins that dock and release neurotransmitter packets — the “slips into those endings and cuts the docking protein” beat

    PubMed · PMID 24975322 · DOI · 10.1038/nrmicro3295

  6. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34(11):853-869.

    Covers: the toxin silenced the slow (C-fiber) pain fibers of the brain lining, reversed established sensitization and prevented it from developing when given first — the mechanistic basis of “fewer alarms reach the brain”

    PubMed · PMID 24694964 · DOI · 10.1177/0333102414527648

  7. Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels. Cephalalgia. 2016;36(9):875-886.

    Covers: injections under the scalp reached and quieted the pain fibers of the brain lining inside the skull — why a map on the outside of the head can act on the endings that matter

    PubMed · PMID 26984967 · DOI · 10.1177/0333102416636843

  8. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406-1418.

    Covers: the PREEMPT injection paradigm — fixed sites across seven muscle areas of the head and neck plus optional “follow-the-pain” sites — the “following the nerves, plus a few where it hurts” beat

    PubMed · PMID 20958294 · DOI · 10.1111/j.1526-4610.2010.01766.x

  9. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. Headache. 2017;57(5):766-777.

    Covers: the anatomical landmarks for each of the 31 fixed sites in the seven muscle groups (corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinals, trapezius) — the map the animation's points of light were placed from; the paper stresses that each patient's anatomy varies and the injector adapts the sites to it

    PubMed · PMID 28387038 · DOI · 10.1111/head.13074

  10. Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851-859.

    Covers: 1,997 treated patients across four double-blind trials — neck pain 12.6%, muscle weakness 8.0%, musculoskeletal stiffness 6.1%, eyelid droop 4.6%, mostly mild to moderate; 3.4% discontinued for side effects — the “a sore neck or a heavy eyelid” beat

    PubMed · PMID 24628923 · DOI · 10.1111/ene.12393

  11. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936.

    Covers: 1,384 adults with chronic migraine, injections every 12 weeks — headache days fell by 8.4 a month with onabotulinumtoxinA versus 6.6 with placebo at week 24 — the “fewer headache days” beat, and why the benefit is measured in days

    PubMed · PMID 20487038 · DOI · 10.1111/j.1526-4610.2010.01678.x

  12. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616.

    Covers: in chronic migraine, about 1.9 fewer headache days a month than placebo (high-quality evidence); in episodic migraine, no difference — the honest effect size behind “the goal is fewer headache days”, and why the indication is chronic migraine only

    PubMed · PMID 29939406 · DOI · 10.1002/14651858.CD011616.pub2

  13. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373.

    Covers: up to five treatment cycles every 12 weeks; by week 56 the reduction in headache days had grown to 11.7 a month in the group treated from the start — the “builds over repeated cycles” beat

    PubMed · PMID 21883197 · DOI · 10.1111/j.1526-4610.2011.01990.x

  14. Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain. 2019;20(1):12.

    Covers: 715 patients treated for nine cycles over 108 weeks; the authors conclude that “a longer duration of treatment was required to fully realize the treatment effect” — the second half of “builds over repeated cycles”

    PubMed · PMID 30709333 · DOI · 10.1186/s10194-018-0953-0

  15. BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use — US Prescribing Information. Allergan, Inc. (an AbbVie company). DailyMed, U.S. National Library of Medicine; label updated November 18, 2023.

    Covers: the approved indication — prophylaxis of headaches in adult patients with chronic migraine (15 or more days per month with headache lasting 4 hours a day or longer) — and the boxed warning for distant spread of toxin effect: swallowing and breathing difficulties, which can be life-threatening, and generalized weakness have been reported hours to weeks after injection — the “rarely… if that happens, call your doctor” beat

    DailyMed · full prescribing information

  16. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609.

    Covers: across 12 population-based studies, chronic migraine affected 0–5.1% of people, typically 1.4–2.2% — the basis for “roughly one to two in a hundred adults”

    PubMed · PMID 19614702 · DOI · 10.1111/j.1468-2982.2009.01941.x

  17. Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019;92(3):134-144.

    Covers: the systematic red-flag list for headaches that are not migraine — sudden “thunderclap” onset, fever or other systemic symptoms, new neurological deficit, a new headache after 50, or a change in pattern — which warrant urgent evaluation rather than a preventive plan

    PubMed · PMID 30587518 · DOI · 10.1212/WNL.0000000000006697

Common questions about Botox for chronic migraine

Same molecule, different job. In chronic migraine, onabotulinumtoxinA is taken up by the sensory nerve endings that wrap the scalp and the lining of the brain, where it cleaves a docking protein (SNAP-25) so those endings can't release the signaling chemicals — CGRP among them — that drive an attack. A 2020 narrative review concluded that the traditional 'reducing muscle contractions' explanation is insufficient for migraine, which is primarily a sensory neurological disease. The injection map, the dose, and the goal are all different from cosmetic use. Source: Burstein 2020 (Headache); Durham 2004 (Headache).

In the United States, onabotulinumtoxinA is approved for the prevention of headaches in adults with chronic migraine — by definition, headache on 15 or more days a month for more than three months, with the headache lasting four hours a day or longer. A Cochrane review found no benefit in episodic migraine (fewer than 15 headache days a month). It is a preventive treatment given on a schedule, not a rescue treatment for an attack already under way. Source: US Prescribing Information (DailyMed, 2023); ICHD-3 (Cephalalgia 2018); Herd 2018 (Cochrane).

In the pooled PREEMPT trials, people with chronic migraine had 8.4 fewer headache days a month at 24 weeks with onabotulinumtoxinA versus 6.6 fewer with placebo. The Cochrane review puts the placebo-adjusted benefit at about 1.9 fewer headache days a month — high-quality evidence, and a modest effect measured in days, not a cure. The benefit accrued across repeated 12-week cycles, and a longer course was needed to see the full effect. Source: Dodick 2010 (Headache); Herd 2018 (Cochrane); Aurora 2011 (Headache); Young 2019 (J Headache Pain).

In a pooled safety analysis of 1,997 treated patients, the most common effects were neck pain (12.6%), muscle weakness (8.0%), muscle stiffness (6.1%), and eyelid droop (4.6%) — mostly mild to moderate; 3.4% stopped treatment because of side effects. All botulinum toxin products carry a boxed warning for distant spread of toxin effect: trouble swallowing or breathing, or generalized weakness, reported hours to weeks after injection. Those symptoms need a call to your doctor or urgent care. Source: Diener 2014 (Eur J Neurol); US Prescribing Information (DailyMed, 2023).

Because the map follows the nerves, not the pain. The published PREEMPT protocol uses 31 fixed sites across seven muscle areas of the forehead, temples, back of the head, neck, and upper shoulders — where the sensory endings of the trigeminal and upper cervical nerves are distributed — with a few optional 'follow-the-pain' sites. The injecting physician adapts the map to your anatomy. Source: Blumenfeld 2010 (Headache); Blumenfeld 2017 (Headache); Burstein 2020 (Headache).

Is Botox the right next step for you? What the pattern means, and what we do about it

Not sure which row is yours? The two-minute chronic migraine Botox eligibility check walks the label and the insurance criteria and ends at the right next step.

Headache on 15 or more days a month, at least 8 of them migraine, for more than three months; oral preventives tried

Usually: Chronic migraine — the FDA-approved indication

At Modal Pain: PREEMPT-protocol Botox (155 units, 31 sites) every 12 weeks; we handle the prior authorization

Fewer than 15 headache days a month

Usually: Episodic migraine — Botox is not indicated and showed no benefit in trials

At Modal Pain: Nerve blocks for flares and neurology-managed prevention (CGRP antibodies, gepants)

Headache that starts at the neck or skull base and never switches sides

Usually: Cervicogenic headache or occipital neuralgia — a migraine look-alike

At Modal Pain: C2–3 / third occipital or occipital nerve block

Botox for chronic migraine and the nerve blocks above are covered by most commercial PPO plans with prior authorization, which our office handles. We do not participate with Medicare or Medicaid. Self-pay pricing is published. Insurance details · Self-pay pricing

Verify my insurance Book an evaluation (646) 290-6660

369 Lexington Ave, Floor 25, New York, NY 10017 · same-week appointments are routinely available · in-suite ultrasound and fluoroscopy.

Go deeper on this site

More in this series

Other mechanism animations

Headache more days than not?

Chronic migraine has a name, a definition, and a mechanism — and a preventive treatment approved for exactly that diagnosis. Dr. Movshis evaluates whether onabotulinumtoxinA fits your history and, when it does, performs the injections in-office in Midtown Manhattan. Botox (onabotulinumtoxinA) is a prescription treatment; whether it is right for you is a decision made with a physician.

Book an Appointment (646) 290-6660 Free Insurance Check
5.0 81 Google Reviews Dual ABA Board-Certified Anesthesiology & Pain Medicine 369 Lexington Ave, Floor 25 Midtown Manhattan, NYC 10017

Educational only — not medical advice. Nothing on this page is medical advice, a diagnosis, or a guarantee of any outcome. Botox (onabotulinumtoxinA) is a prescription medicine; it carries a boxed warning for distant spread of toxin effect — trouble swallowing or breathing, or weakness that spreads, hours to weeks after an injection, needs a call to your doctor or urgent care. A sudden, worst-ever headache, a headache with fever and a stiff neck, or a headache with new neurological symptoms is not chronic migraine and needs urgent medical care.[17]

★★★★★
5 out of 5 based on 81 reviews
View all reviews on Google →

"From the day one, it was very clear I was in the hands of someone who truly cares. Dr. Movshis diagnosed my lumbar disc herniation with nerve compression to the details way…"

★★★★★
Dpak N3 months ago

"Dr. Alex is amazing, the kind of doctor you wish for in every way: punctual, professional, caring, thorough, knowledgeable. He helped me immensely with severe tennis elbow and I…"

★★★★★
Niels Alpert3 months ago

"Dr. Alex is an amazing doctor. Helped me with my back pain. His office is a one stop shop for all pain needs."

Modal Pain Management NYC
369 Lexington Ave, Floor 25
View on Google Maps →